“Waste not, want not”, or the cost of doing the wrong thing  by Kirpalani, Haresh & Zupancic, John
J Pediatr (Rio J). 2016;92(1):1--3
www.jped.com.br
EDITORIAL
‘‘Waste  not,  want  not’’,  or the cost  of doing  the wrong
thing,
‘‘Waste  not,  want  not’’,  ou  o  custo  da  opc¸ão  errada
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In  1995,  Sinclair  pointed  out  that  it  had  taken  an  inordinately
long  time  to  understand  that  we  had  synthesized  adequate
evidence  on  antenatal  corticosteroids  (ANCS)  to  prevent
respiratory  distress  syndrome  (RDS)  and  its  complications
in  preterms.1 Secondly,  it  then  took  even  longer  for  the
knowledge  to  be  disseminated  into  practice.  The  dissem-
ination  problem  was  addressed  by  the  NIH  in  a  speciﬁc
trial  to  enhance  uptake  of  knowledge  on  ANCS  by  the
obstetric  community  over  ‘standard’  methods  of  teaching.2
In  that  cluster  randomized  trial,  a  package  of  teaching
interventions  aimed  at  the  high-risk  perinatal  caregivers
improved  the  uptake  of  ANCS  in  target  populations  of  moth-
ers  at  risk  of  preterm  delivery  by  108%.  Yet  it  appears  that
despite  these  two  seminal  ‘wake-up  calls’  to  the  commu-
nity  --  and  despite  the  recommendations  of  key  bodies  such
as  ACOG3,4 --  the  omission  of  ANCS  continues  to  plague
perinatal--neonatal  medicine.  For  example,  between  2005
and  2007  in  California,  Lee  found  that  ‘‘of  15,343  eligi-
ble  neonates,  23.1%  did  not  receive  antenatal  steroids  in
2005--2007.’’5 Of  these,  a  higher  proportion  of  Hispanic
mothers  did  not  receive  ANCS  --  25.6%.5 Disseminating  this
knowledge-based  practice  into  poorly  resourced  or  lower
income  countries  has  been  even  more  challenging.6,7
 Please cite this article as: Kirpalani H, Zupancic J. ‘‘Waste not,
want not’’, or the cost of doing the wrong thing. J Pediatr (Rio J).
2016;92:1--3.
 See paper by Ogata et al. in pages 24--31.
∗ Corresponding author.
E-mail: kirpalanih@email.chop.edu (H. Kirpalani).
r
s
e
i
e
o
i
s
s
w
http://dx.doi.org/10.1016/j.jped.2015.11.001
0021-7557/© 2015 Sociedade Brasileira de Pediatria. Published by Elsevi,  Boston,  United  States
In  this  issue  of  the  Jornal  de  Pediatria,  Ogata  et  al.
e-emphasize  the  importance  of  the  use  of  ANCS  in  the  pre-
ention  of  neonatal  premature  death,  especially  in  the  poor
nd  middle-income  countries.8 To  further  convince  the  peri-
atal  community,  Ogata  et  al.  performed  a  cost-analysis  of
he  effects  of  ANCS  on  total  hospital  costs  in  Brazil  --  a
iddle-income  country.8 Ogata  et  al.  have  shown  us  that
he  potential  cost  reduction  is  still  large  in  a  very  recent
ohort.  In  surviving  infants  less  than  30  weeks  of  gestational
ge,  there  was  a  38%  reduction  in  total  costs,  presumably
riven  by  a  49%  reduction  in  neonatal  intensive  care  unit
NICU)  length  of  stay.8
Previous  cost-analyses  on  ANCS  were  performed  in  an  ear-
ier  era,9,10 but  in  developed  and  high-income  countries.  In
he  UK,  Mugford  applied  expected  odds  of  death  derived
rom  randomized  trials9 to  the  observed  deaths  in  a  UK
ospital.  This  allowed  them  to  estimate  the  anticipated
mproved  survival,  and  thus  the  hospital  costs  per  extra
urvivor.  They  found  that  in  infants  under  31  weeks  of  gesta-
ional  age  (GA),  the  actual  cost  per  survivor  would  have  been
educed  by  10%.  This  was  despite  the  projected  increased
urvival  rate  --  which  would  be  expensive.9 Similarly,  mod-
ling  data  from  the  USA  showed  projected  cost-savings
n  1995  with  a  minimum  of  $197,000  savings  in  hospital
xpenditure.10 These  data  are  from  the  1990s.  The  ﬁndings
f  Ogata  et  al.  strikingly  conﬁrm  these  earlier  reports,  but
n  a  middle-income  country.A  potential  issue  not  fully  clariﬁed  by  any  of  the  three
tudies8--10 relates  to  possible  misclassiﬁcation  of  the  expo-
ure  to  ANCS.  Speciﬁcally,  mothers  in  the  current  study
ere  classiﬁed  as  receiving  treatment  if  they  received  any
er Editora Ltda. All rights reserved.
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oses  of  the  medication.  In  a  very  comprehensive  population
atabase  in  Nova  Scotia  (from  1988  to  2012),  ‘‘suboptimal
xposure  to  ANCS’’  (deﬁned  as  less  than  24  h  or  more  than
even  days  before  delivery)  comprised  34%  of  deliveries.11
ncomplete  dosing  in  the  ‘‘treated’’  group  would  potentially
ias  the  observed  effectiveness  of  ANCS  toward  the  null,  so
he  actual  effect  might  be  even  higher  than  demonstrated
ere.  Conversely,  in  the  group  who  did  not  receive  ANCS,
here  is  the  potential  for  confounding  by  indication:  moth-
rs  who  did  not  receive  treatment  may  have  been  too  sick,
r  proceeded  to  precipitous  or  complicated  deliveries  with-
ut  any  delay  for  corticosteroid  administration.  In  this  case,
he  non-treated  infants  might  have  been  destined  for  worse
utcomes,  and  the  effect  of  ANCS  would  be  over-estimated.
n  California,  Lee  did  ﬁnd  that  failure  to  receive  ANCS  was
ssociated  with  such  factors  as  fetal  distress.5 Interestingly,
nfants  undergoing  vaginal  delivery  (vs.  cesarean)  were  also
ssociated  with  non-ANS  receipt.5
Another  note  of  caution  concerns  the  speciﬁc  popula-
ion  that  should  be  targeted  in  low-  and  middle-income
ountries.  This  issue  has  been  thrown  into  recent  con-
iderable  debate  following  the  Antenatal  Corticosteroid
reatment  trial  (ACT).12 This  cluster  randomized  clinical
rial  (RCT)  in  six  low-to-middle  income  countries  showed
 higher  28-day  neonatal  mortality  in  all  infants  receiving
NCS  (RR:  1.12;  95%  CI:  1.02--1.22).  However,  the  pri-
ary  outcome  of  the  trial  was  28-day  mortality  in  infants
5th  percentile,  which  showed  no  statistically  signiﬁcant
ifference  (RR:  0.96;  95%  CI:  0.87--1.06).  The  secondary
utcome  of  total  mortality  has  of  course  received  much
ttention,  as  the  results  stand  in  stark  contrast  to  a
eta-analysis  on  rates  of  neonatal  death  from  RDS.6
wansa-Kambafwile  et  al.  pooled  four  trials  in  middle-
ncome  countries  (total  number  of  infants  =  672)  and  showed
 reduction  in  neonatal  mortality  [RR:  0.47  (0.35,  0.64)]
hich  appeared  to  show  even  greater  effect  than  that
bserved  in  developed  countries  (n  =  3284  infants  in  14  stud-
es)  [RR  0.79  (95%  CI  0.65--0.96)].6 In  the  ACT,  eligibility  was
eﬁned  by  use  of  a  tape-measure  of  uterine  height.  It  is
ossible  that  this  led  to  mis-classiﬁcation  of  infants,  as  sug-
ested  by  Visser  and  DiRenzo.13 It  is  further  possible  that
nfants  at  gestational  ages  of  >34  weeks  are  less  likely  to
eneﬁt,  due  to  the  lower  incidence  of  respiratory  distress
yndrome,  but  might  still  be  exposed  to  as-yet-undeﬁned
isks  of  the  medication.  Indeed,  such  exposure  was  frequent
n  the  Nova  Scotia  study  noted  earlier.11 Moreover,  ANCS
hould  ideally  be  part  of  a  continuum  of  best  practices  in
he  intrapartum  and  post-partum  period,  and  suboptimal
esuscitation  or  hygiene  measures  might  adversely  impact
he  effectiveness  of  antepartum  treatment.
We  should  note  that  the  lack  of  evidence  penetra-
ion  into  practice  remains  a  problem  in  parts  of  the
orld,  despite  both  efﬁcacy  data  from  the  1990s1 and
he  economic  data  for  the  same  period.9,10 Potential  cost
eductions  are  huge,  and  worthy  of  the  obstetrician’s  and
eonatologist’s  attention.  Mangham  et  al.  found  an  inverse
elationship  between  both  GA  and  BW,  and  the  costs  of
ospitalization.14 Total  United  Kingdom  costs  of  newborn
are  for  the  extremely  preterm  were  staggeringly  high,
t  £ 94,740  (US$  146,847)  higher  than  a  term  survivor.  Yet
ata  on  the  economic  aspects  of  health  care  on  speciﬁc
herapies  is  remarkably  sparse,  and  what  is  available  is  ofKirpalani  H,  Zupancic  J
ow  methodological  quality.15,16 Moreover,  data  from  large
ethodologically  rigorous  randomized  controlled  clinical
rials  can  and  should  incorporate  economic  analyses.17--19
There  remains  resistance  from  some  physicians  to
ost  analyses,  likely  related  to  multiple  factors  includ-
ng  perceived  infringement  of  autonomy  and  philosophical
bjections  to  ‘limiting  care.’  However,  given  that  resources
or  health  care  are  constrained,  particularly  in  low-  and
iddle-income  countries,  it  is  essential  that  those  resources
re  focused  on  the  highest-yield  therapies.  Such  therapies
ave  an  acceptable  balance  of  costs  and  efﬁcacy  in  improv-
ng  outcomes,  as  summarized  in  the  efﬁcacy/cost  ratio,  or
‘value  equation.’’20 To  that  end,  emphasis  has  recently
een  placed  on  eliminating  practices  that  are  costly  while
aving  poor  evidence  for  effectiveness.  This  approach  has
een  used  in  the  ‘‘Choosing  Wisely’’  campaign,  in  the  United
tates  and  elsewhere,  in  which  medical  subspecialties  iden-
ify  lists  of  ﬁve  practices  that  should  be  reconsidered.21
qually  important,  however,  are  those  practices  that  have
ood  evidence  for  efﬁcacy  but  are  not  being  used  in  all
ligible  patients.  Such  errors  of  omission,  by  foregoing
mprovements  in  outcome  that  would  themselves  reduce
osts,  are  also  wasteful.  As  shown  by  Ogata  et  al.,  antena-
al  corticosteroids  are  a  prime  example  of  such  underused,
ut  effective,  therapies,  and  should  be  targeted  in  quality
mprovement  initiatives  in  this  setting.
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